{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:41:56Z","timestamp":1767832916791,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.riam.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T08:01:28Z","timestamp":1542873688000},"page":"217-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["El tratamiento de la mucormicosis (cigomicosis) en el siglo xxi"],"prefix":"10.1016","volume":"35","author":[{"given":"Isabel","family":"Ruiz Camps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Salavert Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2018.09.001_bib0170","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: Consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.09.001_bib0175","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.09.001_bib0180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/fmb-2016-0231","article-title":"The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK","volume":"12","author":"Bagshaw","year":"2017","journal-title":"Future Microbiol."},{"key":"10.1016\/j.riam.2018.09.001_bib0185","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2012.03976.x","article-title":"Development of a single tube multiplex real-time PCR to detect the most clinically relevant Mucormycetes species","volume":"19","author":"Bernal-Mart\u00ednez","year":"2013","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.09.001_bib0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin Infect Dis."},{"issue":"Suppl 3","key":"10.1016\/j.riam.2018.09.001_bib0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.09.001_bib0205","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2014.08.006","article-title":"A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation","volume":"21","author":"Fox","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.09.001_bib0210","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00536-11","article-title":"Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis 2001-2009","volume":"55","author":"Hammond","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.09.001_bib0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/jac\/dkp426","article-title":"The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis","volume":"65","author":"Ibrahim","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2018.09.001_bib0230","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.idc.2006.06.003","article-title":"Invasive zygomycosis: Update on pathogenesis, clinical manifestations, and management","volume":"20","author":"Kontoyiannis","year":"2006","journal-title":"Infect Dis Clin North Am."},{"key":"10.1016\/j.riam.2018.09.001_bib0235","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.riam.2018.09.001_bib0240","doi-asserted-by":"crossref","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: A propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect."},{"issue":"Suppl 1","key":"10.1016\/j.riam.2018.09.001_bib0245","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: The RetroZygo Study (2005-2007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0250","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"issue":"10020","key":"10.1016\/j.riam.2018.09.001_bib0255","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.riam.2018.09.001_bib0260","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","article-title":"Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"93","author":"Mousset","year":"2014","journal-title":"Ann Hematol."},{"key":"10.1016\/j.riam.2018.09.001_bib0270","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2009.07738.x","article-title":"Zygomycosis: Current approaches to management of patients with haematological malignancies","volume":"146","author":"Pagano","year":"2009","journal-title":"Br J Haematol."},{"key":"10.1016\/j.riam.2018.09.001_bib0275","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.riam.2014.05.002","article-title":"Enfermedad f\u00fangica invasiva por Scedosporium. Fusarium y Mucor","volume":"31","author":"Pem\u00e1n","year":"2014","journal-title":"Rev Iberoam Micol."},{"key":"10.1016\/j.riam.2018.09.001_bib0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.riam.2014.07.002","article-title":"Enfermedad f\u00fangica invasiva por hongos filamentosos","volume":"31","author":"Pem\u00e1n","year":"2014","journal-title":"Rev Iberoam Micol."},{"issue":"Suppl 1","key":"10.1016\/j.riam.2018.09.001_bib0285","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0290","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0295","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: A review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis."},{"issue":"Suppl_1","key":"10.1016\/j.riam.2018.09.001_bib0300","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol."},{"key":"10.1016\/j.riam.2018.09.001_bib0305","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study: A randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2018.09.001_bib0310","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.riam.2018.09.001_bib0315","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/13693780701796973","article-title":"Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital","volume":"46","author":"Torres-Narbona","year":"2008","journal-title":"Med Mycol."},{"issue":"Suppl 5 (s5)","key":"10.1016\/j.riam.2018.09.001_bib0320","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2009.02986.x","article-title":"Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis","volume":"15","author":"Tragiannidis","year":"2009","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.09.001_bib0325","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases","volume":"42","author":"Van Burik J-AH","year":"2006","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.09.001_bib0330","first-page":"1","article-title":"Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections","volume":"8","author":"Wiederhold","year":"2016","journal-title":"Clin Pharmacol."}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140618300561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140618300561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T20:43:58Z","timestamp":1572986638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140618300561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1130140618300561"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2018.09.001","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El tratamiento de la mucormicosis (cigomicosis) en el siglo xxi","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}